The FDA has granted expedited access pathway designation to Second Sight Medical Products for its Orion cortical visual prosthesis system, according to a company press release.
The designation, given to select medical devices, is intended to help patients have more timely access to devices by expediting their development, assessment and review, the release said.
“These advantages potentially allow the FDA to approve Orion with fewer patients and with a shorter follow-up timeline, thus facilitating a faster entry of Orion into the commercial market,” Will McGuire, president and CEO
Uncategorized